Sren Bregenholt - Alligator Bioscience Chief Officer

All Insiders . Sweden . 
Stock . Alligator Bioscience AB . Stakeholders . Insider . Sren Bregenholt
ATORX Stock  SEK 0.56  0.01  1.82%   

Insider

Sren Bregenholt is Chief Officer of Alligator Bioscience AB
Age 52
Phone46 4 65 40 82 00
Webhttps://www.alligatorbioscience.se

Alligator Bioscience Management Efficiency

The company has return on total asset (ROA) of (0.4821) % which means that it has lost $0.4821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0417) %, meaning that it generated substantial loss on money invested by shareholders. Alligator Bioscience's management efficiency ratios could be used to measure how well Alligator Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.
Alligator Bioscience AB has accumulated 3.51 M in total debt with debt to equity ratio (D/E) of 5.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alligator Bioscience has a current ratio of 9.46, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Alligator Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Alligator Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alligator Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alligator to invest in growth at high rates of return. When we think about Alligator Bioscience's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Anne LannerHansa Biopharma AB
54
Dominique TersagoCantargia AB
61
Emanuel BjrneHansa Biopharma AB
50
Jan MattssonBioArctic AB
63
MarcussCantargia AB
N/A
Katja MargellHansa Biopharma AB
N/A
Johanna FltingBioArctic AB
51
Ignacio GarciaRibasCantargia AB
N/A
Jakob LicOncopeptides AB
51
Klaus SindahlHansa Biopharma AB
N/A
Kjell SjstrmCantargia AB
N/A
Annika MBAOncopeptides AB
57
Gunilla OsswaldBioArctic AB
62
Kristina LuthmanOncopeptides AB
N/A
Pr MDOncopeptides AB
N/A
Johanna ChristensenCantargia AB
N/A
Adnan DeronicCantargia AB
N/A
Thoas MDCantargia AB
61
MSc MDOncopeptides AB
N/A
Susanne LagerlundCantargia AB
N/A
Frida LekanderBioArctic AB
N/A
Alligator Bioscience AB develops antibody-based pharmaceuticals for cancer treatment. Alligator Bioscience AB was founded in 2001 and is headquartered in Lund, Sweden. Alligator Bioscience operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 56 people. Alligator Bioscience AB (ATORX) is traded on Stockholm Exchange in Sweden and employs 53 people.

Management Performance

Return On Equity-1.04
Return On Asset-0.48

Alligator Bioscience Leadership Team

Elected by the shareholders, the Alligator Bioscience's board of directors comprises two types of representatives: Alligator Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alligator. The board's role is to monitor Alligator Bioscience's management team and ensure that shareholders' interests are well served. Alligator Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alligator Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sumeet MD, Chief Officer
Malin Carlsson, Ex RD
Marie Svensson, Chief Officer
Julie Silber, Director Relations
Peter Ellmark, Vice President Discovery
Sren Bregenholt, Chief Officer

Alligator Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alligator Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.04
Return On Asset-0.48
Operating Margin(5.39) %
Current Valuation236.82 M
Shares Outstanding220.58 M
Shares Owned By Insiders51.92 %
Shares Owned By Institutions11.58 %
Price To Book2.57 X
Price To Sales17.76 X
Revenue12.94 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Alligator Stock Analysis

When running Alligator Bioscience's price analysis, check to measure Alligator Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alligator Bioscience is operating at the current time. Most of Alligator Bioscience's value examination focuses on studying past and present price action to predict the probability of Alligator Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alligator Bioscience's price. Additionally, you may evaluate how the addition of Alligator Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY